NOVARTIS AG - 28 Oct 2025 Form 3 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
10%+ Owner
Signature
/s/ Jonathan Emery As Attorney
Issuer symbol
TRML
Transactions as of
28 Oct 2025
Net transactions value
$0
Form type
3
Filing time
28 Oct 2025, 12:12:41 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
NOVARTIS AG 10%+ Owner LICHTSTRASSE 35, BASEL, SWITZERLAND /s/ Jonathan Emery As Attorney 28 Oct 2025 0001114448

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TRML Common Stock, par value $0.0001 24,030,382 28 Oct 2025 See Footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are owned directly by Torino Merger Sub Inc., an indirect wholly-owned subsidiary of Novartis AG.